title: Topical formulation engendered alteration in p53 and cyclobutane pyrimidine dimer expression in chronic photodamaged patients.
abstract: While the clinical attributes of photoaging are well characterized in the literature, the pathogenic mechanisms that underlie these changes are incompletely elucidated. At the molecular level, p53 tumor-suppressor gene product mediated excision repair of ultraviolet (UV)-induced DNA damage is a critical effector in xeroderma pigmentosum (XP) and potentially in conventional photoaging. We examined p53 activity and measured UV-induced DNA damage via cyclobutane pyrimidine dimers (CPDs) quantitatively in 20 volunteers before and after an 8-week, open-label prospective topical application of a proprietary DNA recovery serum (Celfix). There was a statistically significant decrease in immunohistochemically determined p53 and CPD levels. While these data are preliminary, the findings lend support to the theoretical possibility of a topical agent reversing the effects of photodamage at the molecular level and, potentially, an ameliorative outcome clinically.
authors.affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Spencer
authors.forename: Michael B
authors.initials: MB
authors.lastname: Morgan
authors.forename: Kara M
authors.initials: KM
authors.lastname: Trapp
authors.forename: Summer D
authors.initials: SD
authors.lastname: Moon
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004249:DNA Damage / Q000187:drug effects / Q000528:radiation effects; D004260:DNA Repair / Q000187:drug effects / Q000528:radiation effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011740:Pyrimidine Dimers / Q000235:genetics* / Q000378:metabolism; D015595:Skin Aging / Q000187:drug effects* / Q000528:radiation effects; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D003879:Dermatologic Agents; D011740:Pyrimidine Dimers; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53